CR20110046A - Amidofenoxiindazoles utiles como inhibidores de c-met - Google Patents
Amidofenoxiindazoles utiles como inhibidores de c-metInfo
- Publication number
- CR20110046A CR20110046A CR20110046A CR20110046A CR20110046A CR 20110046 A CR20110046 A CR 20110046A CR 20110046 A CR20110046 A CR 20110046A CR 20110046 A CR20110046 A CR 20110046A CR 20110046 A CR20110046 A CR 20110046A
- Authority
- CR
- Costa Rica
- Prior art keywords
- useful
- amidophenoxyindazols
- met inhibitors
- inhibitors
- met
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
La presente invención se refiere a compuestos de amidofenoxiindazol útiles en el tratamiento de cáncer.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US8329408P | 2008-07-24 | 2008-07-24 | |
US8508208P | 2008-07-31 | 2008-07-31 | |
US10865908P | 2008-10-27 | 2008-10-27 |
Publications (1)
Publication Number | Publication Date |
---|---|
CR20110046A true CR20110046A (es) | 2011-04-27 |
Family
ID=41010247
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CR20110046A CR20110046A (es) | 2008-07-24 | 2011-01-24 | Amidofenoxiindazoles utiles como inhibidores de c-met |
Country Status (36)
Country | Link |
---|---|
US (2) | US8030302B2 (es) |
EP (1) | EP2310382B1 (es) |
JP (1) | JP5414794B2 (es) |
KR (1) | KR101334456B1 (es) |
CN (1) | CN102105462B (es) |
AR (1) | AR074632A1 (es) |
AT (1) | ATE546444T1 (es) |
AU (1) | AU2009274256B2 (es) |
BR (1) | BRPI0916286B8 (es) |
CA (1) | CA2731773C (es) |
CL (1) | CL2011000134A1 (es) |
CO (1) | CO6351737A2 (es) |
CR (1) | CR20110046A (es) |
CY (1) | CY1112595T1 (es) |
DK (1) | DK2310382T3 (es) |
DO (1) | DOP2011000009A (es) |
EA (1) | EA018385B1 (es) |
EC (1) | ECSP11010778A (es) |
ES (1) | ES2379587T3 (es) |
HK (1) | HK1155172A1 (es) |
HR (1) | HRP20120202T1 (es) |
IL (1) | IL210490A (es) |
JO (1) | JO2788B1 (es) |
MA (1) | MA32594B1 (es) |
MX (1) | MX2011000925A (es) |
MY (1) | MY163852A (es) |
NZ (1) | NZ590013A (es) |
PE (1) | PE20110150A1 (es) |
PL (1) | PL2310382T3 (es) |
PT (1) | PT2310382E (es) |
RS (1) | RS52261B (es) |
SI (1) | SI2310382T1 (es) |
SV (1) | SV2011003816A (es) |
TW (1) | TWI365185B (es) |
WO (1) | WO2010011538A1 (es) |
ZA (1) | ZA201100219B (es) |
Families Citing this family (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2340244A4 (en) | 2008-10-14 | 2012-07-25 | Ning Xi | COMPOUNDS AND APPLICATION PROCEDURES |
RU2011142597A (ru) | 2009-03-21 | 2013-04-27 | Саншайн Лейк Фарма Ко., Лтд. | Производные сложных эфиров аминокислот, их соли и способы применения |
MY181439A (en) | 2011-02-28 | 2020-12-22 | Sunshine Lake Pharma Co Ltd | Substituted quinoline compounds and methods of use |
US8962623B2 (en) * | 2011-03-04 | 2015-02-24 | Locus Pharmaceuticals, Inc. | Aminopyrazine compounds |
KR20130118612A (ko) * | 2012-04-20 | 2013-10-30 | (주)네오믹스 | 신규한 아미노피리딘 유도체 및 이의 용도 |
ES2641444T3 (es) * | 2012-05-09 | 2017-11-10 | Eli Lilly And Company | Procedimiento de preparación de cloruros de 4-[[(benzoil)amino]sulfonil]benzoílo y preparación de acilsulfamoilbenzamidas |
WO2014134313A1 (en) * | 2013-02-27 | 2014-09-04 | Array Biopharma Inc. | Intermediates for use in the preparation of indazole derivatives and processes for the preparation thereof |
CN104140393B (zh) * | 2013-12-10 | 2016-09-21 | 郑州泰基鸿诺医药股份有限公司 | 一种芳环/芳杂环叔丁醇酯类化合物的制备方法 |
EP3134088B1 (en) | 2014-04-22 | 2019-04-10 | Calitor Sciences, LLC | Bicylcic pyrazolone compounds and methods of use |
TW201716085A (zh) * | 2015-08-12 | 2017-05-16 | 應克隆公司 | 癌症之組合療法 |
JP2019511541A (ja) * | 2016-04-15 | 2019-04-25 | イーライ リリー アンド カンパニー | 結腸直腸癌の処置における使用のためのラムシルマブとメレスチニブとの組み合わせ |
BR112018074748A2 (pt) | 2016-06-02 | 2019-03-06 | Immunocore Limited | composição terapêutica biespecífica de redirecionamento de células t, e método de tratamento de câncer gp100 positivo em um paciente |
US20190269666A1 (en) * | 2016-07-29 | 2019-09-05 | Eli Lilly And Company | Combination therapy with merestinib and anti-pd-l1 or anti-pd-1 inhibitors for use in the treatment of cancer |
CN108069938A (zh) * | 2016-11-15 | 2018-05-25 | 中国药科大学 | 2,4-二取代吡啶类化合物及其制备方法和应用 |
EP3541383B1 (en) | 2016-11-16 | 2021-01-06 | Eli Lilly and Company | Combination therapy for cancer with exon 14 skipping mutation(s) or exon 14 skipping phenotype |
US20200054616A1 (en) * | 2016-11-16 | 2020-02-20 | Eli Lilly And Company | Treatment of cancer with exon 14 skipping mutation(s) or exon 14 skipping phenotype |
CN107382968A (zh) * | 2017-07-06 | 2017-11-24 | 北京万全德众医药生物技术有限公司 | 一种吲哚类c‑Met抑制剂的制备方法 |
CN107311983A (zh) * | 2017-07-06 | 2017-11-03 | 北京万全德众医药生物技术有限公司 | 吲哚类小分子c‑met抑制剂 |
US10180422B1 (en) | 2017-08-22 | 2019-01-15 | Scripps Health | Methods of treating a neuroendocrine tumor |
EP3480201A1 (en) | 2017-11-06 | 2019-05-08 | Oncostellae, S.L. | New analogs as androgen receptor and glucocorticoid receptor modulators |
JP7377798B2 (ja) | 2017-11-24 | 2023-11-10 | 南京明徳新薬研発有限公司 | c-MET/AXL阻害剤としてのウラシル系化合物 |
US20210177828A1 (en) * | 2018-01-17 | 2021-06-17 | Nanjing Transthera Biosciences Co., Ltd. | Tam family kinase /and csf1r kinase inhibitor and use thereof |
EP3762392A4 (en) | 2018-03-08 | 2021-09-15 | Wellmarker Bio Co., Ltd. | THIENOPYRIDINE DERIVATIVES AND PHARMACEUTICAL COMPOSITION THEREOF |
BR112021003447A2 (pt) * | 2018-08-24 | 2021-05-18 | Nanjing Transthera Biosciences Co., Ltd. | inibidor derivado de quinolina inovador |
WO2020048455A1 (zh) | 2018-09-03 | 2020-03-12 | 泰励生物科技(上海)有限公司 | 用作抗癌药的trk抑制剂 |
US20230172914A1 (en) | 2019-09-06 | 2023-06-08 | Wellmarker Bio Co., Ltd. | Biomarker-based therapeutic composition |
CN117355533A (zh) * | 2021-06-22 | 2024-01-05 | 株式会社Lg化学 | 作为蛋白激酶抑制剂的新型化合物 |
WO2023110936A1 (en) | 2021-12-14 | 2023-06-22 | Netherlands Translational Research Center Holding B.V | Reversible macrocyclic kinase inhibitors |
Family Cites Families (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NO155316C (no) * | 1982-04-23 | 1987-03-11 | Sintef | Fremgangsmaate for fremstilling av magnetiske polymerpartikler. |
US5484681A (en) * | 1994-10-31 | 1996-01-16 | Xerox Corporation | Conductive composite particles and processes for the preparation thereof |
IL114149A0 (en) * | 1995-06-14 | 1995-10-31 | Yeda Res & Dev | Modified avidin and streptavidin molecules and use thereof |
US5747577A (en) * | 1995-12-27 | 1998-05-05 | Xerox Corporation | Conductive particles containing carbon black and processes for the preparation thereof |
DE10046029A1 (de) | 2000-09-18 | 2002-03-28 | Bayer Ag | Indazole |
KR20040010589A (ko) * | 2001-05-18 | 2004-01-31 | 가부시키가이샤 에스알엘 | 면역 분석법 |
US6956084B2 (en) * | 2001-10-04 | 2005-10-18 | Bridgestone Corporation | Nano-particle preparation and applications |
JP2004067703A (ja) * | 2002-04-24 | 2004-03-04 | Japan Science & Technology Corp | 架橋ポリマー、微粒子および製造方法 |
US7192780B2 (en) * | 2002-10-23 | 2007-03-20 | Evident Technologies | Fluorescent lifetime biological detection and imaging using water-stable semiconductor nanocrystals |
ES2273047T3 (es) | 2002-10-28 | 2007-05-01 | Bayer Healthcare Ag | Fenilaminopirimidinas sustituidas con heteroariloxi como inhibidores de rho-cinasa. |
CN102746529B (zh) * | 2003-07-17 | 2015-11-18 | 生命科技公司 | 包覆的磁性颗粒的制备方法 |
US7163998B2 (en) * | 2003-09-09 | 2007-01-16 | Eastman Kodak Company | Stabilized polymer beads and method of preparation |
US7439246B2 (en) * | 2004-06-28 | 2008-10-21 | Bristol-Myers Squibb Company | Fused heterocyclic kinase inhibitors |
US20050288290A1 (en) * | 2004-06-28 | 2005-12-29 | Borzilleri Robert M | Fused heterocyclic kinase inhibitors |
JO2787B1 (en) | 2005-04-27 | 2014-03-15 | امجين إنك, | Alternative amide derivatives and methods of use |
ME02736B (me) | 2005-12-21 | 2017-10-20 | Janssen Pharmaceutica Nv | Triazolopiridazini kao modulatori tirozin kinaze |
CA2645137A1 (en) * | 2006-03-07 | 2007-09-13 | James F. Blake | Heterobicyclic pyrazole compounds and methods of use |
EP2230264B1 (en) * | 2006-06-29 | 2019-10-09 | Life Technologies AS | Particles containing multi-block polymers |
PE20080403A1 (es) | 2006-07-14 | 2008-04-25 | Amgen Inc | Derivados heterociclicos fusionados y metodos de uso |
KR20090071612A (ko) | 2006-10-23 | 2009-07-01 | 에스지엑스 파마슈티컬스, 인코포레이티드 | 단백질 키나제 조정제로서의 바이시클릭 트리아졸 |
PL2170785T3 (pl) | 2007-06-27 | 2018-12-31 | Arkema Inc. | Sposób wytwarzania fluorowodoroolefin |
-
2009
- 2009-07-10 TW TW098123519A patent/TWI365185B/zh not_active IP Right Cessation
- 2009-07-12 JO JO2009256A patent/JO2788B1/en active
- 2009-07-13 AR ARP090102636A patent/AR074632A1/es active IP Right Grant
- 2009-07-15 AU AU2009274256A patent/AU2009274256B2/en not_active Ceased
- 2009-07-15 EA EA201170252A patent/EA018385B1/ru not_active IP Right Cessation
- 2009-07-15 US US12/503,223 patent/US8030302B2/en not_active Ceased
- 2009-07-15 MY MYPI2011000343A patent/MY163852A/en unknown
- 2009-07-15 JP JP2011520095A patent/JP5414794B2/ja not_active Expired - Fee Related
- 2009-07-15 PT PT09790440T patent/PT2310382E/pt unknown
- 2009-07-15 MX MX2011000925A patent/MX2011000925A/es active IP Right Grant
- 2009-07-15 PL PL09790440T patent/PL2310382T3/pl unknown
- 2009-07-15 SI SI200930193T patent/SI2310382T1/sl unknown
- 2009-07-15 BR BRPI0916286A patent/BRPI0916286B8/pt not_active IP Right Cessation
- 2009-07-15 ES ES09790440T patent/ES2379587T3/es active Active
- 2009-07-15 WO PCT/US2009/050640 patent/WO2010011538A1/en active Application Filing
- 2009-07-15 DK DK09790440.3T patent/DK2310382T3/da active
- 2009-07-15 EP EP09790440A patent/EP2310382B1/en active Active
- 2009-07-15 CA CA2731773A patent/CA2731773C/en not_active Expired - Fee Related
- 2009-07-15 NZ NZ590013A patent/NZ590013A/en not_active IP Right Cessation
- 2009-07-15 RS RS20120176A patent/RS52261B/en unknown
- 2009-07-15 PE PE2011000061A patent/PE20110150A1/es active IP Right Grant
- 2009-07-15 CN CN200980128694.4A patent/CN102105462B/zh not_active Expired - Fee Related
- 2009-07-15 AT AT09790440T patent/ATE546444T1/de active
- 2009-07-15 KR KR1020117001628A patent/KR101334456B1/ko active IP Right Grant
-
2011
- 2011-01-06 IL IL210490A patent/IL210490A/en active IP Right Grant
- 2011-01-07 ZA ZA2011/00219A patent/ZA201100219B/en unknown
- 2011-01-07 DO DO2011000009A patent/DOP2011000009A/es unknown
- 2011-01-19 CO CO11005437A patent/CO6351737A2/es not_active Application Discontinuation
- 2011-01-21 CL CL2011000134A patent/CL2011000134A1/es unknown
- 2011-01-21 EC EC2011010778A patent/ECSP11010778A/es unknown
- 2011-01-21 SV SV2011003816A patent/SV2011003816A/es active IP Right Grant
- 2011-01-24 CR CR20110046A patent/CR20110046A/es unknown
- 2011-01-24 MA MA33555A patent/MA32594B1/fr unknown
- 2011-09-08 HK HK11109520.7A patent/HK1155172A1/xx not_active IP Right Cessation
- 2011-12-08 US US13/374,053 patent/USRE43878E1/en not_active Expired - Fee Related
-
2012
- 2012-03-01 HR HR20120202T patent/HRP20120202T1/hr unknown
- 2012-04-04 CY CY20121100337T patent/CY1112595T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CR20110046A (es) | Amidofenoxiindazoles utiles como inhibidores de c-met | |
ECSP11011441A (es) | Compuestos vinil indazolilo | |
CL2016001733A1 (es) | Compuestos intermediarios para la preparación de compuestos derivados de piperidinona como inhibidores mdm2 para el tratamiento de cáncer div. sol. 3415-12. | |
MA32938B1 (fr) | Composes organiques | |
CR20110467A (es) | Derivados de benzofuranilo como inhibidores de la glucoquinasa | |
HN2007015177A (es) | Derivados de triazolopirazina | |
UY31432A1 (es) | Compuestos de diarilhidantoina | |
BRPI1010795A2 (pt) | compostos antivirais | |
CR20120295A (es) | Triazolopiridinas | |
CR20110686A (es) | Pirimidinonas como ihnibidores de pi3k | |
PA8841901A1 (es) | Compuestos orgánicos | |
CR20120641A (es) | Compuestos macrocìclicos como inhibidores de quinasa trk | |
CR20120297A (es) | Espironucleósidos uracílicos oxetánicos | |
CR20140468A (es) | Inhibidores de diacilglicerol aciltransferasa 2 | |
UY34165A (es) | ?compuestos aldh-2 mitocondriales humanos para el tratamiento de la adicción?. | |
ME01665B (me) | Analozi buprenorfina | |
UY33929A (es) | Compuestos de ciclohexilo tetrasustituido como inhibidores de quinasas | |
GT200800075S (es) | Diseño de embudo | |
CR20130539A (es) | Triazolopiridinas | |
DOP2010000302A (es) | Antagonistas de la trayectoria hedgehog de ftalazina disustituida | |
UY32553A (es) | Nuevos derivados de la pirrolidinadiona espiroheterocíclicos 3-sustituidos | |
CR20150132A (es) | Profármacos de aminoquinazolina inhibidora de cinasa | |
BR112012019302A2 (pt) | imidazo[1,2-b][1,2,4]triazinas como inibidores de c-met | |
UA106889C2 (uk) | Похідні n1-ацил-5-фторпіримідинону | |
GT200700074A (es) | Fungicidas |